India, June 9 -- Shares of IN8bio Inc. (INAB) slipped over 20% on Monday morning. The clinical-stage biopharmaceutical company announced that Patient 009 in the phase 1 trial of INB-200 for newly-diagnosed GBM has recently reached a significant clinical milestone.
INAB is currently trading at $3.2700, down $0.9000 or 21.6346%, on the Nasdaq. The stock opened its trading at $3.5600 after closing Friday at $4.1700. The stock has traded between $2.8200 and $52.2000 in the past 52-week period.
The patient, with a grade 4, IDH-mutant glioma, has been in remission and surviving for 4 years having been treated with INB-200.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The patient is doing well, has retur...